Oxford Finance

Inhibrx, Inc. is a clinical-stage biotechnology company based in La Jolla, California, dedicated to developing a diverse pipeline of novel biologic therapeutic candidates. The company employs advanced protein engineering techniques, including its proprietary sdAb platform, to target complex disease biology, with a focus on oncology, orphan diseases, and infectious diseases. Inhibrx's lead candidates include INBRX-109, a multivalent agonist in Phase 1 trials for solid tumors; INBRX-105, an antagonist of PD-L1 also in Phase 1 trials; INBRX-101, an Fc-fusion protein for alpha-1 antitrypsin deficiency; and INBRX-103, a monoclonal antibody targeting CD47. Additionally, the company is developing preclinical programs such as INBRX-106, an agonist of OX40, and INBRX-111, an antibody targeting Pseudomonas aeruginosa. Inhibrx has established collaborations with organizations like Celgene and Bluebird Bio and has received funding from various granting agencies, including the NIH and CARB-X.

Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapeutics for rare diseases. The company's primary focus is on its lead candidate, Diazoxide Choline Controlled Release (DCCR), a once-daily oral tablet designed for the treatment of Prader-Willi Syndrome (PWS). DCCR contains diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. Currently, the product is being evaluated in a Phase III clinical development program. Established in 1999 and headquartered in Redwood City, California, Soleno Therapeutics was formerly known as Capnia, Inc. before rebranding in May 2017.

Verona Pharma is a clinical-stage biopharmaceutical company based in London, established in 2005. The company specializes in developing and commercializing therapies for respiratory diseases that have significant unmet medical needs, including chronic obstructive pulmonary disease (COPD), cystic fibrosis, and asthma. Its lead product candidate, ensifentrine, is an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, functioning as both a bronchodilator and an anti-inflammatory agent. Ensifentrine is being developed in various formulations, including nebulized, dry powder inhaler, and pressurized metered-dose inhaler, with the nebulized form currently in Phase 2b clinical development for the maintenance treatment of COPD. Verona Pharma's commitment is to enhance the health and quality of life for individuals suffering from chronic respiratory conditions through innovative therapeutic solutions.

Headspace is a company dedicated to enhancing mental healthcare through its digital platform, which focuses on meditation, mindfulness, and overall mental well-being. The Headspace app features a diverse array of guided meditations led by experts, including its co-founder Andy Puddicombe, aimed at helping users reduce stress, improve focus, and cultivate mindfulness. It also offers specialized tools for sleep, such as "Sleepcasts," soundscapes, and guided sleep meditations, to aid users in achieving better rest. In addition to these features, Headspace provides mindfulness programs that address various aspects of daily life, including work, relationships, and health, while also focusing on managing mental health challenges like anxiety and depression. Furthermore, the company collaborates with organizations through corporate wellness programs, supplying resources designed to enhance employee productivity and well-being.

Amino Inc. operates an online platform designed to assist users in finding doctors, comparing their qualifications, and scheduling appointments across the United States. The platform enables patients to search for healthcare providers based on specific conditions, procedures, and specialties. In addition to this, Amino functions as a healthcare financial wellness platform, helping companies and their employees navigate the complexities of the U.S. healthcare system. It focuses on delivering data-driven, personalized care recommendations that encourage plan members to seek high-value healthcare options. Through its services, Amino aims to make healthcare more intuitive, accessible, and convenient for patients. The company, originally known as Pare Labs, Inc., was incorporated in 2013 and rebranded to Amino in 2014, with its headquarters located in San Francisco, California.

Amino Inc. operates an online platform designed to assist users in finding doctors, comparing their qualifications, and scheduling appointments across the United States. The platform enables patients to search for healthcare providers based on specific conditions, procedures, and specialties. In addition to this, Amino functions as a healthcare financial wellness platform, helping companies and their employees navigate the complexities of the U.S. healthcare system. It focuses on delivering data-driven, personalized care recommendations that encourage plan members to seek high-value healthcare options. Through its services, Amino aims to make healthcare more intuitive, accessible, and convenient for patients. The company, originally known as Pare Labs, Inc., was incorporated in 2013 and rebranded to Amino in 2014, with its headquarters located in San Francisco, California.

Pearl Street Dental Management operates as a dental practice management company focused on providing support to dental practices across Texas and Oklahoma. The firm specializes in non-clinical operations, offering centralized services that include human resources, payroll, accounting, bookkeeping, finance, lending, facilities management, and information technology. By equipping partner dentists with advanced technology and resources, Pearl Street Dental enables the delivery of comprehensive care in general, specialty, and cosmetic dentistry. The company addresses inquiries through various channels, including online applications, phone calls, and emails, ensuring effective communication and support for its partners.

Renibus Therapeutics is a clinical-stage biotech company transforming outcomes in cardiothoracic surgical patients. It has developed a portfolio of products that activate multiple cytoprotective pathways, including organ protection via preconditioning.

ALX Oncology is a clinical-stage immuno-oncology company based in Burlingame, California, established in 2015. The company specializes in developing innovative therapies aimed at treating various forms of cancer, with a particular focus on its lead product candidate, ALX148. This therapeutic agent is designed to block the CD47 protein, which cancer cells exploit to evade the immune system. ALX148 is currently being investigated for its efficacy in treating myelodysplastic syndromes, acute myeloid leukemia, and several solid tumor types, including head and neck squamous cell carcinoma and certain gastric cancers. The company leverages advanced protein engineering technologies to enhance the affinity of its CD47 blockers, aiming to minimize hematologic toxicities often associated with existing treatments. ALX Oncology's commitment to improving cancer therapies is rooted in pioneering research conducted by its founders at Stanford University.

Verona Pharma is a clinical-stage biopharmaceutical company based in London, established in 2005. The company specializes in developing and commercializing therapies for respiratory diseases that have significant unmet medical needs, including chronic obstructive pulmonary disease (COPD), cystic fibrosis, and asthma. Its lead product candidate, ensifentrine, is an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, functioning as both a bronchodilator and an anti-inflammatory agent. Ensifentrine is being developed in various formulations, including nebulized, dry powder inhaler, and pressurized metered-dose inhaler, with the nebulized form currently in Phase 2b clinical development for the maintenance treatment of COPD. Verona Pharma's commitment is to enhance the health and quality of life for individuals suffering from chronic respiratory conditions through innovative therapeutic solutions.

Antheia is a biotechnology company focused on developing plant-inspired medicines through innovative biomanufacturing processes. Utilizing synthetic biology and fermentation technology, Antheia reconstructs complex molecules in yeast to produce active pharmaceutical ingredients (APIs) without relying on medicinal plants. This approach enhances the efficiency of drug manufacturing and discovery, allowing for cost-competitive and reliable production of essential medicines. By transforming the pharmaceutical supply chain, Antheia aims to ensure consistent availability of natural and healthier medications for healthcare organizations and their patients.

SeLux Diagnostics, Inc. is a biotechnology company based in Charlestown, Massachusetts, founded in 2014. It specializes in developing a next-generation phenotyping platform for antibiotic susceptibility testing and diagnostics of infectious diseases. The company utilizes a synthetic amplifier technology that enhances the speed and complexity of antibiotic susceptibility testing, facilitating quicker and more accurate selection of personalized antimicrobial therapies for patients. By streamlining the identification of effective treatments, SeLux Diagnostics aims to improve patient care, reduce hospital stays, and tackle the growing issue of antibiotic resistance by minimizing the reliance on broad-spectrum antibiotics.

Silk Road Medical, Inc. is a medical device company based in Sunnyvale, California, specializing in the treatment of carotid artery disease through its innovative transcarotid artery revascularization (TCAR) approach. Founded in 2007, the company develops and manufactures minimally invasive devices aimed at reducing the risk of stroke and improving patient outcomes. Its product portfolio includes the ENROUTE Transcarotid Neuroprotection System, which facilitates direct access to the common carotid artery while ensuring temporary blood flow reversal to protect the brain, and the ENROUTE Transcarotid Stent System, a self-expanding stent supported by clinical data on safety outcomes. Additionally, the ENHANCE Transcarotid Peripheral Access Kit and the ENROUTE 0.014 Guidewire are designed to aid in gaining access and delivering interventional devices effectively. Silk Road Medical aims to establish TCAR as the standard of care for carotid artery disease treatment.

Verastem, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative treatments aimed at improving the survival and quality of life for cancer patients. Based in Needham, Massachusetts, Verastem markets COPIKTRA (duvelisib), an oral medication indicated for adult patients with relapsed or refractory chronic lymphocytic leukemia and follicular lymphoma after multiple prior therapies. In addition to this approved therapy, the company is advancing its pipeline with the focal adhesion kinase inhibitor defactinib, which is being studied in combination with immunotherapies for various cancers, including pancreatic and ovarian cancers, as well as non-small cell lung cancer. Verastem's research emphasizes inhibiting critical signaling pathways that promote cancer cell survival and tumor growth, particularly those associated with the RAS/MAPK pathway. The company has formed collaborative agreements with Yakult Honsha Co., Ltd. and CSPC Pharmaceutical Group Limited to enhance its development efforts. Founded in 2010, Verastem continues to focus on late-stage development of its anticancer agents.

Lexicon Pharmaceuticals is a biopharmaceutical company focused on the discovery, development, and commercialization of pharmaceutical products to treat various human diseases. The company's portfolio includes several drug candidates in different stages of clinical trials. LX9211 is an orally-delivered small molecule being tested for neuropathic pain treatment. Sotagliflozin, another orally-delivered small molecule, is under investigation for heart failure and type 1 diabetes. Additionally, the company has developed LX4211 for type 2 diabetes, LX2931 for rheumatoid arthritis and other autoimmune diseases, and LX7101 for glaucoma treatment. Lexicon Pharmaceuticals has established collaborations with several pharmaceutical companies, including Bristol-Myers Squibb, Genentech, Organon, Takeda, Symphony Icon, Taconic Farms, and Nuevolution A/S.

Centogene is a prominent genetic biotech company specializing in the diagnosis and analysis of rare inherited diseases. Headquartered in Rostock, Germany, with additional operations in Berlin and Cambridge, Massachusetts, Centogene focuses on transforming clinical, genetic, and biochemical data into actionable medical solutions. The company serves a diverse global patient population and aims to enhance awareness and understanding of rare diseases across various ethnicities. Centogene operates in two main segments: diagnostics, which offers targeted genetic sequencing and diagnostic services, and pharmaceuticals, which collaborates with partners to provide services such as patient recruitment, biomarker discovery, and epidemiological insights. Through its comprehensive approach, Centogene is dedicated to advancing the field of human genetics and improving the lives of patients and their families affected by rare diseases.

Sierra Oncology, Inc. is a clinical-stage biopharmaceutical company that focuses on developing and commercializing therapies for patients with hematology and oncology needs. The company's lead drug candidate, momelotinib, is an orally bioavailable inhibitor targeting JAK1, JAK2, and ACVR1, which has undergone two completed Phase 3 trials for myelofibrosis treatment. Additionally, Sierra Oncology is advancing SRA737, a small molecule inhibitor of Checkpoint kinase 1 currently in Phase 1/2 clinical trials, and SRA141, an inhibitor of cell division cycle 7 kinase, which is in preclinical development. Founded in 2003 and headquartered in Vancouver, Canada, Sierra Oncology aims to provide targeted therapies for rare forms of cancer, leveraging scientific expertise to address limitations in existing treatments and improve patient outcomes. The company was previously known as ProNAi Therapeutics, Inc. before its name change in January 2017.

Choice Health at Home, LLC is a Texas-based provider of home health, hospice, rehabilitation, and personal care services, established in 2007 and headquartered in Tyler. The company specializes in delivering comprehensive care primarily for geriatric patients, offering a range of services that include routine care, nursing, medical consultations, and rehabilitation therapies such as physical, speech, and occupational therapy. Choice Health at Home is committed to providing continuous care that transitions seamlessly from hospital settings to patients' homes, ensuring that individuals receive the support they need throughout their recovery and daily living.

Kezar Life Sciences, Inc. is a clinical-stage biotechnology company specializing in the discovery and development of small molecule therapeutics aimed at addressing unmet medical needs in autoimmunity and cancer. The company's lead candidate, KZR-616, is a selective immunoproteasome inhibitor currently undergoing Phase 2 clinical trials for various autoimmune conditions, including lupus nephritis and autoimmune hemolytic anemia, as well as Phase 1b/2 trials in systemic lupus erythematosus. In addition to KZR-616, the company is developing KZR-TBD, which targets both oncology and autoimmune disorders. Founded in 2015 and based in South San Francisco, California, Kezar Life Sciences leverages insights from protein homeostasis to advance its drug discovery efforts.

Viracta Therapeutics, Inc. is a clinical-stage drug development company based in Cardiff, California, that specializes in precision oncology focused on virus-associated malignancies. The company utilizes a viral activation therapy platform to develop treatments for cancers linked to the Epstein-Barr Virus (EBV) and other virus-related diseases. Its lead investigational drug, nanatinostat, is being evaluated in combination with the antiviral valganciclovir as a potential oral therapy for EBV-positive lymphoma, including post-transplant lymphoproliferative disorder, plasmablastic lymphoma, and angioimmunoblastic T cell lymphoma. Viracta is also exploring the application of this approach to other EBV-associated conditions, such as nasopharyngeal carcinoma and gastric carcinoma. Founded in 2007 and rebranded from HemaQuest Pharmaceuticals in 2015, Viracta Therapeutics is actively conducting multiple clinical trials to advance its therapeutic candidates.

Platelet BioGenesis, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in the production of donor-independent human platelets derived from pluripotent stem cells for clinical use. Founded in 2014, the company has developed a microfluidic bioreactor designed to generate functional platelets from human stem cell cultures at a commercial scale. These bioreactor-produced platelets are distributed to hospitals and blood banks, providing a vital resource for patients worldwide. The company is also focused on advancing therapeutics within the fields of biotechnology and drug discovery.

4D pharma plc is a research and development company based in Leeds, United Kingdom, specializing in the production of live biotherapeutic products. Founded in 2014, the company focuses on a range of therapeutic areas, including autoimmune diseases, central nervous system disorders, and cancer. Its proprietary MicroRx platform is designed to identify novel bacteria that can provide targeted therapeutic effects, utilizing single strains of bacteria naturally present in the human gut. 4D pharma's product pipeline includes programs for conditions such as irritable bowel syndrome, pediatric Crohn's disease, asthma, and various solid tumors. Currently, the company has two programs in clinical trials and plans to initiate three additional programs in the near future. Notably, 4D pharma has entered into a collaboration with Merck & Co. to evaluate the combination of one of its products with Keytruda for the treatment of solid tumors.

Impel Pharmaceuticals is a late-stage pharmaceutical company that specializes in developing and commercializing innovative therapies for patients with significant unmet medical needs, particularly in central nervous system disorders. The company employs its proprietary Precision Olfactory Delivery (POD) system to enhance drug delivery directly to the vascular-rich upper nasal space, facilitating the administration of various therapeutic formulations. Impel's product pipeline includes TRUDHESA™, designed for the acute treatment of migraines, INP105 for managing agitation and aggression in individuals with autism, and INP107 for addressing OFF episodes in Parkinson’s disease. By focusing on these transformative therapies, Impel aims to improve patient outcomes and address critical health challenges.

Kala Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for eye diseases using its proprietary Mucus Penetrating Particles (MPP) technology. This technology enhances drug distribution and pharmacokinetics by coating mucosal surfaces with biocompatible, drug-loaded particles, allowing for improved local drug concentrations while minimizing systemic exposure. Kala's lead product candidate, KPI-121 0.25%, has completed two Phase III clinical trials aimed at providing temporary relief for dry eye disease. Additionally, INVELTYS has also completed two Phase III trials for managing inflammation and pain after ocular surgery. The company is advancing KPI-285, a receptor tyrosine kinase inhibitor, in preclinical studies targeting retinal diseases. Established in 2009 and headquartered in Watertown, Massachusetts, Kala Pharmaceuticals continues to explore diverse product opportunities while focusing on internal development and research collaborations to address significant clinical needs.

Mainstay Medical, based in Dublin, Ireland, with operations in the U.S. and Australia, is a medical device company specializing in the development and commercialization of innovative treatments for chronic low back pain. Its flagship product, ReActiv8, is an implantable neurostimulation system designed to restore muscle control and improve function in the lumbar spine, thereby enhancing patients' quality of life. Founded in 2008, the company collaborates with scientists and clinical experts to address the significant unmet need in this large, underserved patient population.

Immunocore Limited is a biotechnology company based in Abingdon, United Kingdom, with a focus on discovering and developing novel therapeutics for cancer, viral diseases, and autoimmune conditions. The company specializes in T cell receptor (TCR) technology, which allows it to create innovative bispecific immunotherapies. Its lead product candidate, IMCgp100, is currently undergoing clinical trials for the treatment of metastatic melanoma. Immunocore's proprietary platform enables efficient manufacturing of TCR-based drugs, addressing significant unmet medical needs. Founded in 1999 and previously known as Avidex Limited, Immunocore has expanded its operations with an additional office in Conshohocken.

Greenbrook TMS owns and operates healthcare centers providing repetitive transcranial magnetic stimulation therapy (TMS) for the treatment of major depressive disorder (MDD) and other neurological diseases. Local electromagnetic stimulation is given during TMS therapy to certain brain areas known to be directly involved in mood regulation. Spravato is promoted to treat depressive symptoms in adults with MDD who have suicidal thoughts or behaviors as well as adults with treatment-resistant depression. In order to give patients a thorough treatment experience, Greenbrook handles insurance coverage and handles logistics while keeping the clients informed and involved in the procedure.

Nature's Fynd is a Chicago-based food company that specializes in producing a unique protein derived from a microbe found in geothermal springs. Founded in 2012 and originally known as Sustainable Bioproducts, Inc., the company focuses on creating sustainable food options that benefit both consumers and the environment. Utilizing innovative fermentation technology, Nature's Fynd is able to cultivate protein using significantly less land and water compared to conventional agricultural methods. The company also operates an additional office in Bozeman, Montana, and aims to contribute to a more sustainable food system through its revolutionary approach to protein production.

RxSight, Inc. is a medical technology company focused on enhancing vision outcomes for patients after cataract surgery. Based in Aliso Viejo, California, the company develops the RxSight Light Adjustable Lens system, which includes the Light Adjustable Lens (LAL) and the Light Delivery Device (LDD). This innovative system allows surgeons to customize and optimize patients' visual acuity post-surgery, making it the first commercially available intraocular lens technology that enables such personalization. The LAL incorporates ActivShield™ technology, a unique UV protection layer that further enhances its functionality. Founded in 1997 and originally known as Calhoun Vision, RxSight changed its name in 2017 to reflect its commitment to advancing ophthalmic care through precision lens technology.

Scholar Rock is a biotechnology company focused on discovering and developing innovative therapies that target dysregulated growth factors within disease microenvironments. Founded in 2012 and based in Cambridge, Massachusetts, the company employs a proprietary platform to create monoclonal antibodies that selectively modulate the activation of these signaling proteins. This approach aims to avoid traditional challenges associated with growth factor inhibition while facilitating efficient drug development. Scholar Rock's lead product, SRK-015, is designed as a first-in-class inhibitor of myostatin activation, targeting conditions such as spinal muscular atrophy. The company's pipeline includes additional candidates, such as SRK-181, which inhibits latent transforming growth factor beta-1 for cancer treatment. Scholar Rock's research focuses on serious diseases, including neuromuscular disorders, cancer, fibrosis, and autoimmune diseases, reflecting its commitment to transforming patient outcomes through targeted therapies.

SpendMend is a healthcare organization that focuses on helping healthcare entities identify and mitigate financial leakage. The company provides spend visibility and audit recovery services aimed at detecting payment errors and contract non-compliance within clients' operating expenses. By utilizing a technology-driven platform, SpendMend enables healthcare organizations to generate cost savings and enhance their cost cycle management. This approach not only helps clients shrink financial losses but also prevents future occurrences, effectively addressing control gaps that can lead to over-payments.

ReMed provides rehabilitation services, neurobehavioral services, and supported living for people with mild, moderate, and severe brain injuries. They offer residential, outpatient, and home and community-based treatment.

Vedanta Biosciences, Inc. is a clinical-stage microbiome company based in Cambridge, Massachusetts, focused on developing therapies for immune-mediated and infectious diseases using human microbiome-derived bacteria. Established in 2010, the company utilizes microbial ecology and mucosal immunology to create innovative immunotherapies. Its platform includes a comprehensive library of bacteria sourced from the human microbiome, proprietary assays for selecting effective bacterial strains, and extensive datasets from human interventional studies. Vedanta also possesses cGMP-compliant manufacturing capabilities, allowing for the production of defined bacterial consortia in powder form. This enables the development of oral therapies aimed at treating autoimmune and inflammatory diseases, providing physicians with effective access to live bacterial drugs. Vedanta operates as a subsidiary of Pure Tech Health plc.

Enable Injections, LLC specializes in the design and manufacture of disposable, body-worn bolus injectors that facilitate the delivery of high viscosity and volume injectable drugs directly into subcutaneous tissue. Established in 2010 and based in Cincinnati, Ohio, the company’s innovative devices can utilize standard containers such as vials, syringes, or cartridges. These injectors not only allow for the reconstitution of powdered drugs but also enable the delivery of up to 20 ml of medication. The system automatically warms and mixes lyophilized solutions, ensuring a seamless injection experience. Additionally, Enable Injections offers a version of its platform that can connect to smartphones via Bluetooth, enhancing user interaction. With approximately 900 new drugs in development that may benefit from this technology, the market for bolus injection systems is projected to reach $8 billion within the next decade.

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's proprietary platform utilizes advances in immunobiology and nanotechnology to create targeted immunomodulatory nanoparticles. Selecta's lead product, SEL-212, has successfully completed Phase II clinical trials for chronic refractory gout. Additionally, the company is advancing gene therapy candidates in preclinical development for rare metabolic disorders, including SEL-302 for methylmalonic acidemia and SEL-313 for ornithine transcarbamylase deficiency. Founded in 2007 and headquartered in Watertown, Massachusetts, Selecta Biosciences has established collaborations with various organizations, including Spark Therapeutics and the Massachusetts Institute of Technology, to enhance its research and development capabilities.

Epic Healthcare Staffing is a diversified national provider of staffing services to the healthcare and bio-pharmaceutical industries.

Syros Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in developing innovative treatments for cancer and monogenic diseases through gene control medicines. The company is advancing its lead product candidates, including SY-1425, a selective retinoic acid receptor alpha agonist currently in Phase II clinical trials for specific patient populations with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor under investigation in a Phase I clinical trial for advanced solid tumors. Syros is also engaged in collaborative research, including a partnership with Incyte Corporation aimed at identifying therapeutic targets for myeloproliferative neoplasms and a licensing agreement with TMRC Co. Ltd. for the development of tamibarotene. With a focus on mapping gene regulatory circuits, Syros leverages its proprietary platform and expertise to address significant unmet medical needs in oncology. Founded in 2011, the company aims to establish new standards of care for patients with hematologic malignancies.

GenapSys, Inc. develops innovative DNA sequencing technologies aimed at enhancing applied genomic testing and medical sequencing. Its primary product, the GenapSys Sequencer, utilizes a proprietary electrical-based detection method for single nucleotide incorporations, making it suitable for a wide range of applications, including research, gene editing, drug development, agriculture, forensics, and food testing. The sequencer is designed for versatility, allowing it to operate in various lab environments and automate clonal amplification. GenapSys is also focused on collaborating with local health agencies and researchers to facilitate rapid sequencing capabilities that can aid in controlling outbreaks. Its compact design enables deployment in diverse locations, such as hospitals and public transport hubs, for efficient virus sample analysis. Founded in 2010 and headquartered in Redwood City, California, GenapSys is committed to providing accessible and precise genetic testing solutions.

DermCare Management is a dermatology practice management company founded by experienced dermatology professionals. It focuses on partnering with dermatologists to enhance patient loyalty and practice growth by combining clinical expertise with management support. The company provides administrative assistance and resources, allowing dermatologists to concentrate on delivering high-quality care. DermCare Management aims to foster a team-oriented environment in healthcare, emphasizing collaboration and effective management to ensure the continued success of its partner practices. Through its services, DermCare Management addresses the unique challenges faced by dermatology practices, enabling them to thrive in a competitive landscape while maintaining a commitment to exceptional patient care.

Equillium Inc is a biotechnology company focused on developing innovative therapies for autoimmune and inflammatory disorders that have significant unmet medical needs. The company's leading product candidate, EQ001, is a first-in-class monoclonal antibody that specifically targets the immune checkpoint receptor CD6, which is crucial in regulating effector T cell activity associated with various immuno-inflammatory diseases, including graft-versus-host disease, asthma, uveitis, colitis, lupus, and multiple sclerosis. In addition to EQ001, Equillium's pipeline includes itolizumab, an antibody targeting the CD6-ALCAM pathway, which is undergoing Phase 3 trials for acute graft-versus-host disease and Phase 1b trials for lupus nephritis. The company is also advancing EQ101, a cytokine inhibitor aimed at IL-2, IL-9, and IL-15, which is poised to enter Phase 2 studies for alopecia areata, and EQ102, another cytokine inhibitor that targets IL-15 and IL-21, which is ready for clinical development.

LogicBio Therapeutics is a genome editing company dedicated to developing innovative treatments for rare diseases, particularly those affecting pediatric patients with significant unmet medical needs. Utilizing its proprietary GeneRide technology, LogicBio aims to integrate corrective genes into patients' genomes, offering potential therapeutic benefits. The company's lead product candidate, LB-001, targets Methylmalonic Acidemia, a severe condition that manifests at birth. Additionally, LogicBio is advancing other candidates, including LB-301, which is being developed in collaboration with Takeda Pharmaceutical Company for Crigler-Najjar syndrome. The company also partners with the Children's Medical Research Institute to create new viral vectors. Founded in 2014 and based in Lexington, Massachusetts, LogicBio is focused on delivering safe and effective genetic medicine to patients suffering from previously untreatable genetic and infectious diseases.

Xeris Biopharma Holdings is a specialty pharmaceutical company focused on developing and commercializing innovative therapies for patients in endocrinology, neurology, and gastroenterology. The company utilizes its proprietary formulation technologies, XeriSol and XeriJect, to create ready-to-use, liquid-stable injectables that facilitate subcutaneous and intramuscular delivery of various therapeutic agents. Xeris offers three commercially available products: Gvoke, a liquid glucagon for severe hypoglycemia; Keveyis, the first FDA-approved treatment for primary periodic paralysis; and Recorlev, approved for endogenous hypercortisolemia in adults with Cushing's Syndrome. Xeris Biopharma's formulation platforms aim to improve patient and caregiver ease of use by eliminating reconstitution, ensuring long-term stability at room temperature, and reducing injection volume, thereby enhancing healthcare delivery and potentially lowering costs for the healthcare system. The company is also advancing a pipeline of development programs to expand its product offerings.

Codex DNA is a biology company helping researchers with the tools they need to securely design, code, and create synthetic DNA. The company is on a mission to help scientific researchers in both academic and commercial settings with the hardware, software, materials, and methodologies required to rapidly and accurately write large quantities of synthetic genes. To, in effect, build biology. Its gene synthesis portfolio reduces the turnaround time for synthesizing workflows from weeks and months to days and hours and includes the BioXp system, DNA services, Gibson Assembly reagents, and Vmax chemically competent cells. In addition to automating, speeding, and optimizing DNA design and synthesis, Codex DNA and the BioXp system ensure your designs stay in your hands, marrying speed and security for innovators in drug discovery, vaccine development, precision medicine, and beyond. Co-founded by Dan Gibson — the creator of the industry-standard Gibson Assembly methodology — Codex DNA is attempting nothing less than changing everything.

MolecuLight specializes in innovative imaging solutions for wound care, particularly in the detection of harmful bacteria and the measurement of wounds. The company develops portable handheld optical imaging devices that allow medical practitioners to visualize bacteria and assess tissue viability at the point of care. These devices facilitate the documentation and monitoring of wound healing progress, enabling healthcare professionals to select the appropriate therapy for their patients in a timely manner. By providing accurate analysis and procedural guidance, MolecuLight's technology aims to enhance patient outcomes in wound management.

ObsEva SA is a clinical-stage biopharmaceutical company based in Geneva, Switzerland, dedicated to developing innovative therapeutics for women's reproductive health and pregnancy. Founded in 2012 by Ernest Loumaye and André Chollet, the company focuses on addressing serious conditions such as endometriosis, heavy menstrual bleeding, and preterm labor. Its key products include Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist aimed at treating pain from endometriosis and uterine fibroids, and OBE022, a selective prostaglandin F2α receptor antagonist designed for once-daily treatment of preterm labor. Additionally, ObsEva is advancing Nolasiban, an oral oxytocin receptor antagonist intended to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. The company operates primarily in Switzerland and is committed to improving outcomes for women facing reproductive health challenges.

Talphera is a specialty pharmaceutical company dedicated to developing and commercializing therapies tailored for medically supervised environments. The company offers innovative products such as NanoTab, designed for oral transmucosal administration, and the Sufentanil NanoTab PCA system, which is a sublingual patient-controlled analgesia system aimed at managing acute postoperative pain in hospital settings. Additionally, Talphera provides Sufentanil NanoTab BTP management systems for cancer pain treatment and Sufentanil/Triazolam NanoTab, which delivers both analgesia and sedation for minor outpatient procedures. The company's diverse portfolio also includes nafamostat product candidates and pre-filled syringe product candidates, reflecting its commitment to addressing critical pain management needs.

RefleXion Medical Inc. is a medical equipment company specializing in the development of biologically-guided radiotherapy systems for cancer treatment. Its flagship innovation, the RefleXion X1 machine, is designed to deliver advanced radiation therapies such as stereotactic body radiotherapy (SBRT) and stereotactic radiosurgery (SRS). The company's biologically-guided radiotherapy (BgRT) technology utilizes positron-emission tomography (PET) imaging data to allow tumors to continuously signal their location during treatment, enabling the possibility of treating multiple tumors in a single session, especially in cases of metastasized cancers. This real-time adaptation to the biological characteristics of tumors represents a significant advancement in radiation oncology. RefleXion Medical, incorporated in 2009 and based in Hayward, California, has established strategic partnerships with Telix Pharmaceuticals Limited and HealthMyne Inc. to further its mission in cancer treatment innovation.

Summit Healthcare REIT, based in Laguna Hills, California, operates as a real estate investment trust (REIT) focusing on the acquisition and ownership of assisted living, memory care, and skilled nursing facilities. Its portfolio spans various geographic regions and is diversified across top-tier operators in the senior housing sector.

Evolus, Inc. is a performance beauty company based in Newport Beach, California, specializing in medical aesthetic products for physicians and their patients in the United States. The company's flagship product, Jeuveau, is a proprietary formulation of purified botulinum toxin type A designed to temporarily improve the appearance of moderate to severe glabellar lines, commonly referred to as frown lines. Evolus targets the self-pay aesthetic market, offering solutions that cater to the needs of aesthetic physicians and their patients. The company has positioned itself to compete with established products in the market by emphasizing the performance characteristics of its formulations. With a customer-centric approach, Evolus aims to provide innovative options for aesthetic treatments and expand choices available in the growing facial aesthetics sector.

Continuing Healthcare Solutions is a provider of long-term care and healthcare services focused on delivering compassionate care to its residents. The company offers a wide range of services, including assisted living, skilled nursing care, rehabilitation services, memory care, behavioral health, respiratory care, wound management, and hospice care. Committed to treating residents with dignity and respect, Continuing Healthcare Solutions aims to establish itself as a preferred provider in the healthcare sector by hiring, training, and retaining quality healthcare professionals. Its emphasis on exceptional care and community leadership positions the company as a trusted option for individuals seeking comprehensive healthcare services.

AliveCor, Inc. specializes in developing digital medical-grade electrocardiograms, enabling users to monitor their heart health through mobile technology. The company's flagship product, KardiaMobile, is a personal mobile EKG device that provides instant detection of common heart arrhythmias, along with features for blood pressure and weight tracking, as well as storage for recorded EKGs. Additionally, AliveCor offers KardiaMobile 6L, a six-lead EKG device that allows patients to share detailed EKG readings with healthcare providers. The company also operates KardiaCare, a digital health subscription service that empowers users to manage their heart health conveniently at home. Founded in 2010 and incorporated in 2011, AliveCor is headquartered in Mountain View, California, and is recognized for its innovative contributions to cardiac care through the integration of machine learning techniques.

Karius, Inc. is a life sciences company based in Redwood City, California, specializing in genomic insights for infectious diseases. The company offers a non-invasive blood test known as the Karius Test, which utilizes sequencing of microbial cell-free DNA to identify and quantify various pathogens, including bacteria, DNA viruses, fungi, and parasites. This test is particularly useful for diagnosing complicated pneumonia, infections in immunocompromised patients, and endocarditis. By mapping the microbial landscape of each patient from a single blood draw, Karius aims to assist clinicians in making rapid and informed treatment decisions. The company's laboratory is CLIA-certified and CAP-accredited, ensuring high standards in clinical laboratory testing. Additionally, Karius provides laboratory services for pathogen biomarker detection tailored to biopharmaceutical companies.

Nevakar Inc. is a pharmaceutical company based in Bridgewater, New Jersey, specializing in the development of innovative ophthalmic and injectable products. Founded in 2015, the company aims to create enhanced formulations of existing FDA-approved molecules to meet unmet clinical and commercial needs. Nevakar's efforts are underpinned by a robust research and development infrastructure situated in the New Jersey Center of Excellence, complemented by a seasoned management and leadership team. Through intensive R&D and clinical initiatives, Nevakar is committed to advancing healthcare solutions in its specialized fields.

QuVa Pharma, Inc. is a 503B outsourcing company that specializes in the manufacturing and supply of compounded sterile preparations. Founded in 2015 and headquartered in Sugar Land, Texas, with additional manufacturing facilities in Temple, Texas, and Bloomsbury, New Jersey, QuVa Pharma produces a range of specialty admixtures in IV bags, syringes, and specialized vials. The company focuses on delivering vital compounded medications for various therapeutic areas, including obstetrics, anesthesia, general medicine, cardiovascular care, and pain management. By serving compliance-oriented healthcare facilities across the United States, QuVa Pharma plays a crucial role in providing ready-to-use pharmaceutical products, including antibiotics, electrolytes, and anesthetics, to hospitals and long-term care facilities.

Cardiac Dimensions, Inc. is a medical device company focused on developing minimally invasive treatments for heart failure and associated cardiovascular conditions. The company is known for its Carillon Mitral Contour System, a permanent implant designed to treat functional mitral regurgitation through a non-surgical, catheter-based approach that reshapes the mitral valve and reduces regurgitation. Established in 2000, Cardiac Dimensions is headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany.

Xeris Biopharma Holdings is a specialty pharmaceutical company focused on developing and commercializing innovative therapies for patients in endocrinology, neurology, and gastroenterology. The company utilizes its proprietary formulation technologies, XeriSol and XeriJect, to create ready-to-use, liquid-stable injectables that facilitate subcutaneous and intramuscular delivery of various therapeutic agents. Xeris offers three commercially available products: Gvoke, a liquid glucagon for severe hypoglycemia; Keveyis, the first FDA-approved treatment for primary periodic paralysis; and Recorlev, approved for endogenous hypercortisolemia in adults with Cushing's Syndrome. Xeris Biopharma's formulation platforms aim to improve patient and caregiver ease of use by eliminating reconstitution, ensuring long-term stability at room temperature, and reducing injection volume, thereby enhancing healthcare delivery and potentially lowering costs for the healthcare system. The company is also advancing a pipeline of development programs to expand its product offerings.

VitalConnect specializes in developing wearable biosensor technology for continuous patient monitoring. The company designs adhesive patches that adhere to the body, enabling the real-time recording of vital signs. By integrating expertise in biomedical engineering, data analytics, and chip design, VitalConnect's products support healthcare professionals in various settings, including hospitals and post-discharge care. The data collected can be easily accessed via mobile devices or computer systems, allowing for immediate response to urgent situations and providing valuable insights into patient health. This technology aims to enhance decision-making processes in clinical environments and improve overall patient care.

Puma Biotechnology is a biopharmaceutical company dedicated to the development and commercialization of innovative products aimed at improving cancer care. The company focuses on acquiring and advancing drug candidates that have completed initial clinical testing. Its primary product, NERLYNX, is an oral formulation of neratinib, which is used for treating HER2-positive breast cancer. In addition to neratinib, Puma is developing PB357, an irreversible tyrosine kinase inhibitor that targets epidermal growth factor receptors HER1, HER2, and HER4. The company has established a licensing agreement with Pfizer for the development and commercialization of these drug candidates. Founded in 2010 and headquartered in Los Angeles, California, Puma Biotechnology is committed to enhancing treatment outcomes for patients with various forms of cancer.

AirXpanders, Inc. was a medical device company founded in 2005 and headquartered in San Jose, California. It specialized in designing, manufacturing, and distributing devices aimed at improving breast reconstruction procedures. The company developed the AeroForm Tissue Expander System, a needle-free, patient-controlled device used for tissue expansion in patients undergoing two-stage breast reconstruction after mastectomy. AirXpanders operated in Australia, the United States, and Europe, focusing on enhancing the experience and outcomes for patients requiring breast reconstruction. However, on September 25, 2019, the company filed for Chapter 7 bankruptcy and ceased operations.

Castle Biosciences, Inc. is a commercial-stage biotechnology company headquartered in Friendswood, Texas, specializing in diagnostic and prognostic tests for dermatological cancers. The company develops innovative genomic tests to aid physicians and patients in making informed treatment decisions. Its flagship product, DecisionDx-Melanoma, is a multi-gene expression profile test designed to identify stage I and II melanoma patients at high risk of metastasis. Additionally, Castle Biosciences offers the DecisionDx-UM test, which assesses the risk of metastasis in patients with uveal melanoma, a rare eye cancer. The company is also advancing two proprietary tests aimed at addressing cutaneous squamous cell carcinoma and suspicious pigmented lesions, both of which represent significant clinical needs in dermatological oncology. Through its products, Castle Biosciences aims to provide personalized and actionable genomic information, thereby enhancing cancer diagnosis and management.

Cerapedics, Inc. is an orthobiologics company based in Westminster, Colorado, specializing in the development and commercialization of its proprietary small peptide technology platform, specifically the biomimetic peptide molecule known as P-15. The company focuses on creating innovative solutions for spinal applications and orthopedic procedures. Its primary offerings include i-FACTOR, a peptide-enhanced bone graft designed to stimulate the natural bone healing process, and i-FACTOR+ MATRIX for surgical implantation. Founded in 2000, Cerapedics aims to provide safer and more predictable bone formation options compared to traditional bone growth factors, thereby enhancing the effectiveness of spinal fusion surgeries and other orthopedic treatments.

Reata Pharmaceuticals is a clinical-stage biopharmaceutical company that develops innovative therapeutics aimed at treating serious and life-threatening diseases by targeting molecular pathways involved in cellular metabolism and inflammation. The company is advancing several clinical trial programs, including bardoxolone methyl for chronic kidney disease related to Alport syndrome and pulmonary arterial hypertension, as well as omaveloxolone for Friedreich’s ataxia. Additionally, Reata is conducting studies for various forms of chronic kidney disease, including IgA nephropathy and diabetic kidney disease. The company is also developing RTA 901 for neurological conditions such as diabetic neuropathy and exploring RORgT inhibitors in preclinical stages for autoimmune and fibrotic diseases. Reata has strategic collaborations with Kyowa Kirin to develop bardoxolone in several Asian markets and with AbbVie to research second-generation Nrf2 activators for various indications. Founded in 2002 and headquartered in Plano, Texas, Reata Pharmaceuticals was previously known as Reata Discovery, Inc. until its name change in 2005.

Oxford BioTherapeutics Ltd is a biotechnology company specializing in the development of targeted antibody-drug conjugates for cancer treatment. Utilizing its proprietary OGAP platform, which is one of the largest human protein databases, the company identifies a range of validated and novel antigen targets from various cancer types. Its leading product, OBT076, is an antibody-drug conjugate aimed at treating high-risk HER2 negative breast cancer, as well as other solid tumors such as gastric, lung, bladder, and ovarian cancers. In addition to its cancer therapies, Oxford BioTherapeutics is also engaged in developing antibody-based treatments for acute myeloid leukemia. The company has formed strategic collaborations with prominent antibody firms to enhance its pipeline of novel therapeutics. Established in 2003 and based in Oxon, United Kingdom, with a presence in San Jose, California, Oxford BioTherapeutics aims to improve patient outcomes through innovative treatments and the integration of companion diagnostics into its development processes.

ConforMIS is a medical technology company based in the United States that specializes in joint replacement implants and instruments. Utilizing its proprietary iFit® Image-to-Implant® technology platform, ConforMIS develops and manufactures personalized implants that are uniquely sized and shaped to match each patient's anatomy. The company's offerings include a wide range of sterile knee and hip implants, such as partial and total knee replacements, along with single-use surgical instruments. ConforMIS's iFit technology encompasses design, printing, and just-in-time delivery, allowing for customized solutions that enhance patient outcomes. The company primarily generates revenue through sales to hospitals and ambulatory surgical centers, positioning itself within the knee replacement market.

Eiger BioPharmaceuticals is a late-stage biopharmaceutical company headquartered in Palo Alto, California, specializing in the development of targeted therapies for rare and ultra-rare diseases. The company's lead product candidate, Lonafarnib, is an orally bioavailable small molecule currently in Phase 3 clinical trials for the treatment of hepatitis delta virus (HDV) infection, a life-threatening condition with significant unmet medical needs. Eiger's pipeline also includes Lambda, which is being evaluated in Phase 2 trials for HDV treatment, and Lonafarnib is being explored for its potential use in treating progeria and progeroid laminopathies. Additionally, Avexitide, which has completed Phase 2 trials for post-bariatric hypoglycemia, is also undergoing clinical evaluation for congenital hyperinsulinism. Eiger's strategic focus is on efficient drug development to deliver safe and effective therapies to patients suffering from these serious conditions.

Strongbridge Biopharma plc is a commercial-stage biopharmaceutical company dedicated to developing and commercializing therapies for rare diseases with significant unmet medical needs. The company’s primary focus is on rare endocrine disorders, exemplified by its product candidates, Recorlev, a cortisol synthesis inhibitor currently in Phase III trials for endogenous Cushing's syndrome, and Veldoreotide, a somatostatin analog that has completed Phase II trials for acromegaly. Strongbridge also offers Keveyis, an oral carbonic anhydrase inhibitor approved for treating specific forms of periodic paralysis in the United States. Founded in 1996 and headquartered in Trevose, Pennsylvania, the company aims to leverage a concentrated prescriber base for its products and plans to utilize a targeted sales force for marketing in the U.S., European Union, and other key markets. Additionally, Strongbridge seeks to enhance its portfolio through the in-licensing or acquisition of complementary products that align with its focus on rare endocrine conditions.

Veran Medical Technologies is a medical device company focused on developing minimally invasive solutions for interventional oncology procedures. Based in St. Louis, Missouri, the company offers a range of products, including the SPiNView thoracic navigation system, which aids physicians in performing biopsies on solitary pulmonary nodules for early lung cancer diagnosis. Other key offerings include the ig4 IR System, a platform that assists in biopsies and ablations for various organs, and the SPiNPerc device for hybrid diagnostic procedures. The company also provides vPad2, a tracking device for instrument positioning during surgery, and the vTrack 2.0 Instruments, which guide physicians to peripheral lung regions. Veran's technology enhances diagnostic accuracy and therapy delivery by integrating various imaging modalities, ultimately aiming to improve patient outcomes through earlier cancer detection and treatment.

Bi02 Medical, Inc. specializes in the design, development, manufacture, and commercialization of medical devices aimed at addressing clinical needs. The company's flagship product, the Angel Catheter, is an inferior vena cava (IVC) filter designed to protect against prophylactic pulmonary embolism and facilitate access to the central venous system in critically ill patients. This device allows for the administration of medications, fluids, and blood products, as well as blood sampling and monitoring of central venous pressure. Bi02 Medical's products are distributed globally through various partners. Founded in 2006, the company is headquartered in San Antonio, Texas, and operates a research and development and manufacturing facility in Golden, Colorado.

CVRx, Inc. is a medical device company based in Minneapolis, Minnesota, that specializes in implantable technology for treating high blood pressure and heart failure. The company develops Barostim, a proprietary neuromodulation therapy that activates the body's natural reflexes to regulate blood pressure and address the progression of heart failure. This therapy is delivered through a long-lasting implant system that is tailored to meet individual patient needs. CVRx also manufactures the Rheos implantable pulse generator and associated components, which facilitate the delivery of activation energy to the carotid arteries. Founded in 2000, CVRx primarily serves patients and healthcare professionals in the United States and several European countries, focusing on minimally invasive solutions for cardiovascular diseases.

Senseonics Holdings, Inc. is a medical technology company based in Germantown, Maryland, specializing in the development and commercialization of continuous glucose monitoring (CGM) systems for individuals with diabetes. Founded in 1996, the company focuses on innovative and long-term implantable glucose monitoring solutions that utilize advanced fluorescence sensing technology. Its flagship products, Eversense and Eversense XL, are implantable CGM systems designed to monitor glucose levels for up to 90 and 180 days, respectively. These products aim to provide users with a reliable and stable means of glucose management, enhancing their ability to live confidently and manage their diabetes effectively. The majority of Senseonics' revenue comes from international markets, reflecting its strong presence in Europe.

Ignyta, Inc. is a biotechnology company focused on discovering, developing, and commercializing molecularly targeted therapies aimed at treating cancer and autoimmune diseases. Established in 2011 and based in San Diego, California, Ignyta is dedicated to advancing personalized medicine by integrating therapeutic approaches with companion diagnostics. Its notable products include entrectinib, a tyrosine kinase inhibitor targeting various receptor proteins, and RXDX-105, which is designed for RET-driven solid tumors. The company seeks to improve treatment outcomes by identifying patients most likely to benefit from specific therapies through biomarker-based diagnostics. In 2018, Ignyta became a subsidiary of Roche Holdings, further enhancing its capabilities in precision medicine.

Monteris Medical, Inc. is a medical device company that specializes in developing and marketing technologies for minimally invasive neurosurgery, particularly focused on the treatment of brain lesions. The company's flagship product, the NeuroBlate System, is a laser thermotherapy system designed for the volumetric ablation of pathological brain lesions, including both primary and metastatic tumors. This system utilizes magnetic resonance imaging (MRI) guidance and applies focused laser energy to effectively target and ablate tumors while minimizing damage to surrounding healthy tissue. Monteris Medical also offers various stereotactic anchoring devices for precise image-guided trajectory alignment, as well as stabilization systems for MRI-based procedures that require head fixation. Founded in 1999 and headquartered in Plymouth, Minnesota, the company serves neurosurgeons across the United States through a dedicated sales force. Monteris Medical was previously known as AutoLITT until rebranding in 2003.

Regulus Therapeutics Inc. is a clinical stage biopharmaceutical company based in San Diego, California, specializing in the discovery and development of therapies that target microRNAs for various diseases. The company is advancing its lead product candidates, RG-012 and RGLS4326, which are in Phase II and Phase Ib clinical trials, respectively. RG-012 targets miR-21 for the treatment of Alport syndrome, a severe kidney disease, while RGLS4326 targets miR-17 for autosomal dominant polycystic kidney disease. In addition to these candidates, Regulus is developing a pipeline of preclinical drug products, including RGLS5579, aimed at inhibiting miR-10b, as well as programs targeting hepatitis B virus and non-alcoholic steatohepatitis. Founded in 2007, Regulus Therapeutics is at the forefront of leveraging the therapeutic potential of microRNA, a significant scientific breakthrough in recent years.

Omeros Corporation is a Seattle-based biopharmaceutical company that focuses on discovering, developing, and commercializing small-molecule and protein therapeutics targeting inflammation, complement-mediated diseases, and disorders of the central nervous system. The company offers OMIDRIA, a product used during cataract surgery in the United States. Omeros is advancing several clinical programs, including narsoplimab, which is in Phase III trials for conditions such as hematopoietic stem-cell transplant-associated thrombotic microangiopathy and immunoglobulin A nephropathy, as well as Phase II trials for lupus nephritis. Other key programs include OMS405, targeting opioid and nicotine addiction, and OMS527, aimed at treating addiction and movement disorders. The company's preclinical pipeline includes compounds addressing various conditions, such as paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders. Founded in 1994, Omeros is dedicated to addressing both large-market and orphan indications through innovative therapeutic approaches.

ADMA Biologics, Inc. is a biopharmaceutical company focused on developing, manufacturing, and marketing specialty plasma-derived biologics aimed at treating immune deficiencies and infectious diseases in the United States. The company offers a range of products, including BIVIGAM and ASCENIV, both intravenous immune globulin therapies for primary humoral immunodeficiency, as well as Nabi-HB, which is used for acute exposure to Hepatitis B. ADMA is also involved in the development of additional plasma-derived therapeutics, particularly targeting infections like S. pneumonia. To support its operations, the company runs FDA-licensed source plasma collection facilities known as ADMA BioCenters, which contribute to the supply of plasma necessary for its product manufacturing. ADMA Biologics distributes its products through independent distributors, sales agents, specialty pharmacies, and other healthcare providers. Founded in 2004 and based in Ramsey, New Jersey, ADMA is dedicated to serving niche patient populations, particularly those with compromised immune systems.

Nuvectra is a medical device company specializing in neurostimulation technology aimed at treating various neurological disorders. The company focuses on developing and commercializing its innovative platform, which stimulates nervous system-associated tissues to address chronic conditions. Nuvectra's primary product is the Algovita Spinal Cord Stimulation (SCS) System, designed to manage chronic pain in the trunk and limbs. Operating mainly in the United States, Nuvectra is dedicated to improving the quality of life for patients suffering from chronic neurological issues through its advanced medical devices.

Superior Biologics is a prominent provider of intravenous and injectable medications tailored for patients with chronic disorders. Headquartered in Hawthorne, New York, the company primarily serves the tri-state area of New York, New Jersey, and Connecticut, while also being licensed to provide services in various other states. Superior Biologics is committed to delivering cost-effective, patient-specific services that empower individuals to maintain normal lives and achieve optimal therapeutic outcomes. The company prioritizes understanding the evolving needs of patients and their families, offering personalized support backed by a team of highly qualified professionals.

Bi02 Medical, Inc. specializes in the design, development, manufacture, and commercialization of medical devices aimed at addressing clinical needs. The company's flagship product, the Angel Catheter, is an inferior vena cava (IVC) filter designed to protect against prophylactic pulmonary embolism and facilitate access to the central venous system in critically ill patients. This device allows for the administration of medications, fluids, and blood products, as well as blood sampling and monitoring of central venous pressure. Bi02 Medical's products are distributed globally through various partners. Founded in 2006, the company is headquartered in San Antonio, Texas, and operates a research and development and manufacturing facility in Golden, Colorado.

Omeros Corporation is a Seattle-based biopharmaceutical company that focuses on discovering, developing, and commercializing small-molecule and protein therapeutics targeting inflammation, complement-mediated diseases, and disorders of the central nervous system. The company offers OMIDRIA, a product used during cataract surgery in the United States. Omeros is advancing several clinical programs, including narsoplimab, which is in Phase III trials for conditions such as hematopoietic stem-cell transplant-associated thrombotic microangiopathy and immunoglobulin A nephropathy, as well as Phase II trials for lupus nephritis. Other key programs include OMS405, targeting opioid and nicotine addiction, and OMS527, aimed at treating addiction and movement disorders. The company's preclinical pipeline includes compounds addressing various conditions, such as paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders. Founded in 1994, Omeros is dedicated to addressing both large-market and orphan indications through innovative therapeutic approaches.

Aratana Therapeutics, Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutics for dogs and cats in the United States. Founded in 2010 and headquartered in Leawood, Kansas, the company focuses on addressing unmet medical needs in companion animal care through high-quality medicines. Its product portfolio includes various therapeutics, such as NOCITA for post-operative pain management in dogs, ENTYCE for appetite stimulation, and GALLIPRANT for pain and inflammation associated with osteoarthritis. Aratana is also advancing treatments for conditions like osteosarcoma in dogs and a range of therapies for cats, including a specialized formulation for pain management and treatments for feline herpes virus-induced conditions. The company has established collaboration agreements with other health organizations to enhance the development and commercialization of its products.

MDRejuvena is dedicated to and passionate about providing products that rejuvenate, enhance, and maintain skin health for the patients of physicians and skincare professionals worldwide. It specializes in the fields of fitness, healthcare, and wellness. It was founded in 2015 and headquartered in San Diego, California.

Zyga Technology, Inc. is a medical device company focused on developing and commercializing minimally invasive products for underserved conditions of the lumbar spine. The company offers the SImmetry Sacroiliac Joint Fusion System, which provides a surgical solution for sacroiliac joint fusion, addressing issues such as joint disruptions and degenerative sacroiliitis. Additionally, Zyga is working on the Glyder Facet Restoration System, an investigational device aimed at treating chronic facetogenic pain. Founded in 2008 and based in Minnetonka, Minnesota, Zyga Technology has assembled a skilled team with extensive experience in the spine industry. As of late 2017, Zyga operates as a subsidiary of RTI Surgical, Inc.

Continuum Health Alliance, LLC ("Continuum") is a regional healthcare management company founded in 1998 by nationally-renowned pediatrician John M. Tedeschi, MD. Continuum offers operational oversight and optimizes business processes, enabling physician groups and hospitals to better serve their patients. The Company's comprehensive service portfolio is built on five pillars. Continuum offers administrative solutions, financial services, revenue cycle management, information technology, and population management services, which addresses new governmental guidelines and healthcare initiatives. Continuum also collaborates with hospitals to create and manage medical group networks, hospitalist programs, and innovative hospital-based programs; and helps medical providers navigate and respond to the regulatory requirements mandated by America's health care reform legislation. The Company presently oversees an aggregate client workforce of more than 4,000 employees located in approximately 200 medical offices and hospital settings

Venus Concept Inc. is a medical aesthetic technology company based in Toronto, Canada, specializing in the development and commercialization of minimally invasive and non-invasive devices and treatments. Its diverse product portfolio includes platforms such as Venus Versa, a multi-treatment solution for aesthetic procedures; Venus Legacy, designed for complex face and body needs; and Venus Viva, a customizable skin resurfacing device. The company also offers solutions for hair restoration, including NeoGraft and ARTAS robotic systems, which facilitate follicle harvesting and implantation. Other products address skin tightening, fat reduction, and vaginal health restoration. Venus Concept is recognized for its innovative approach and commitment to enhancing patient experiences within the medical aesthetics sector, generating a significant portion of its revenue from the United States.

Ocera Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for patients suffering from acute and chronic liver diseases, addressing a significant unmet medical need. The company's lead product, OCR-002, functions as an ammonia scavenger and is being investigated in both intravenous and oral formulations to treat hyperammonemia. Recently, Ocera completed a Phase 2b clinical trial named STOP-HE, which assessed the safety and efficacy of intravenously administered OCR-002 in alleviating neurocognitive symptoms associated with acute hepatic encephalopathy in hospitalized patients with elevated ammonia levels. Ocera is currently preparing for a meeting with the FDA to discuss the intravenous program and explore potential development pathways for its therapeutics.

AlterG, Inc. is a manufacturer and distributor of rehabilitation and therapy equipment, headquartered in Fremont, California. The company specializes in developing innovative devices, most notably the Anti-Gravity Treadmill, which utilizes pressure-unweighting technology to facilitate physical therapy for individuals recovering from lower extremity injuries or surgeries. AlterG also offers the Stride Smart Gait Analytics treadmill, designed to enhance the benefits of anti-gravity therapy, and the AlterG Digital Video Monitoring System, which fosters collaboration between patients and therapists to optimize rehabilitation outcomes. Additionally, the company provides various accessories such as standard and performance shorts, as well as mats, to complement its rehabilitation equipment. Founded in 2004, AlterG aims to empower individuals to achieve their physical goals by improving mobility, reducing pain, and accelerating recovery times.

Pharming Group is a biopharmaceutical company focused on developing protein replacement therapies and precision medicines for patients with rare, debilitating, and life-threatening diseases. The company aims to address the needs of underserved patients by commercializing an innovative portfolio of therapies, including its flagship product, Ruconest. Pharming Group generates its revenue primarily from the United States, where it is committed to transforming the lives of individuals affected by these rare conditions.

ADMA Biologics, Inc. is a biopharmaceutical company focused on developing, manufacturing, and marketing specialty plasma-derived biologics aimed at treating immune deficiencies and infectious diseases in the United States. The company offers a range of products, including BIVIGAM and ASCENIV, both intravenous immune globulin therapies for primary humoral immunodeficiency, as well as Nabi-HB, which is used for acute exposure to Hepatitis B. ADMA is also involved in the development of additional plasma-derived therapeutics, particularly targeting infections like S. pneumonia. To support its operations, the company runs FDA-licensed source plasma collection facilities known as ADMA BioCenters, which contribute to the supply of plasma necessary for its product manufacturing. ADMA Biologics distributes its products through independent distributors, sales agents, specialty pharmacies, and other healthcare providers. Founded in 2004 and based in Ramsey, New Jersey, ADMA is dedicated to serving niche patient populations, particularly those with compromised immune systems.

Labcyte Inc., founded in 2000 and based in San Jose, California, specializes in developing acoustic droplet ejection (ADE) technology for various applications in the life sciences. The company's innovative approach uses focused beams of acoustic energy to precisely dispense nanoliter-scale droplets of fluid from one plate to another, enabling high accuracy at low volumes and reducing consumables costs. Labcyte's products include automation systems, laboratory workstations, and control software, which are utilized in drug discovery, genomics research, cancer research, and personalized medicine. The company operates as a subsidiary of Beckman Coulter, Inc., with additional offices across multiple countries including Canada, the United Kingdom, Australia, India, South Korea, China, Hong Kong, Japan, Singapore, and Taiwan.

Edgemont Pharmaceuticals is a developer of innovative drugs focused on treating psychiatric disorders. The company specializes in creating novel drug formulations and therapies that address various conditions, including major depressive disorder, bulimia nervosa, obsessive-compulsive disorder, and panic disorder. By concentrating on the neuroscience field, Edgemont aims to provide effective solutions that help patients manage and overcome their depression and anxiety challenges. The leadership team at Edgemont brings extensive experience and a proven track record in the pharmaceutical industry and life sciences, further reinforcing the company's commitment to advancing mental health treatments.

Celula, Inc. is a diagnostic testing services company committed to enhancing the accuracy of diagnosing significant diseases, particularly those affecting women, such as gynecologic cancers and non-invasive prenatal diagnoses. The company has developed the Integrated Diagnostic Accuracy (IDA) platform, which combines proprietary and non-proprietary technologies to deliver results that surpass the accuracy of current tests. This platform not only increases the positive predictive value for disease detection but also reduces unnecessary interventions caused by false positives. Results are presented in a customized Integrated Patient Report, aiding decision-making for both patients and physicians. Established in 2005 and headquartered in San Diego, California, Celula also operates a development facility in Chengdu, China, allowing for a capital-efficient approach to product development and commercial expansion. The company operates as a subsidiary of NeoSeq Ltd., enhancing its capacity to innovate in the diagnostic testing space.

ReShape Medical Inc. is a medical device company headquartered in San Clemente, California, specializing in non-surgical weight loss solutions. The company offers the ReShape Integrated Dual Balloon System, which employs dual balloon technology to aid weight loss in adults with a Body Mass Index (BMI) of 30-40 who have not achieved success with diet and exercise alone. This procedure is complemented by a personalized weight loss program that lasts one year. The company's product line includes the FDA-approved Lap-Band System, a minimally invasive treatment for obesity, and the investigational ReShape Vest System, designed to wrap around the stomach and induce weight loss without permanently altering patient anatomy. ReShape Medical's portfolio aims to provide effective alternatives to invasive surgical procedures for managing obesity and related metabolic diseases. The company operates as a subsidiary of EnteroMedics Inc., having undergone a name change in 2017.

Inhibrx, Inc. is a clinical-stage biotechnology company based in La Jolla, California, dedicated to developing a diverse pipeline of novel biologic therapeutic candidates. The company employs advanced protein engineering techniques, including its proprietary sdAb platform, to target complex disease biology, with a focus on oncology, orphan diseases, and infectious diseases. Inhibrx's lead candidates include INBRX-109, a multivalent agonist in Phase 1 trials for solid tumors; INBRX-105, an antagonist of PD-L1 also in Phase 1 trials; INBRX-101, an Fc-fusion protein for alpha-1 antitrypsin deficiency; and INBRX-103, a monoclonal antibody targeting CD47. Additionally, the company is developing preclinical programs such as INBRX-106, an agonist of OX40, and INBRX-111, an antibody targeting Pseudomonas aeruginosa. Inhibrx has established collaborations with organizations like Celgene and Bluebird Bio and has received funding from various granting agencies, including the NIH and CARB-X.

InterValve Inc. specializes in developing medical devices for the catheter-based treatment of calcified aortic valve stenosis. Founded in 2008 and based in Plymouth, Minnesota, the company focuses on creating advanced tools for both percutaneous and trans-apical aortic valve replacement procedures. Its flagship product is the V8 Aortic Valvuloplasty Balloon Catheter, designed to optimize the aortic valve area and minimize movement during procedures. This next-generation balloon catheter features a unique figure 8 shape that locks into valve anatomy, enhancing leaflet hyperextension while reducing the risk of annulus over-distension. InterValve operates as a subsidiary of Venus MedTech (HangZhou) Inc. as of June 2017.

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, dedicated to developing and commercializing therapies for central nervous system diseases. The company's lead product candidate, roluperidone, is in Phase III clinical trials aimed at treating schizophrenia. Additionally, Minerva is advancing seltorexant, which has completed Phase IIb trials for insomnia and major depressive disorders, and MIN-301, currently in pre-clinical trials for Parkinson's disease. Minerva has entered into a license agreement with Mitsubishi Tanabe Pharma Corporation for the global development of roluperidone, excluding Asia, and has a collaboration with Janssen Pharmaceutica for seltorexant. Founded in 2007 and formerly known as Cyrenaic Pharmaceuticals, Minerva Neurosciences focuses on providing innovative therapeutic options for patients with significant unmet medical needs in the CNS space.

Asensus Surgical is a medical device company focused on enhancing minimally invasive surgery through digital laparoscopy. By digitizing the interface between surgeons and patients, the company incorporates advanced technologies such as augmented intelligence, connectivity, and robotics into surgical procedures. Their flagship product, the Senhance Surgical System, is notable for being the first machine vision system designed for robotic surgery. This system is supported by the Intelligent Surgical Unit, which facilitates augmented intelligence in surgery. Asensus Surgical aims to address various clinical, cognitive, and economic challenges faced in surgical practices, ultimately improving patient outcomes through innovative solutions in digital laparoscopy.

Trevena, Inc. is a biopharmaceutical company based in Chesterbrook, Pennsylvania, established in 2007. The company is dedicated to the development and commercialization of innovative medicines aimed at treating central nervous system disorders. Its product candidates include Oliceridine injection, which is designed for managing moderate-to-severe acute pain and has completed Phase III clinical trials, and TRV250, a delta-opioid receptor agonist that has finished Phase I trials for acute migraine treatment. Other candidates in development include TRV734, targeting both acute and chronic pain, and TRV027, which is being evaluated for acute heart failure. Additionally, Trevena is collaborating with Imperial College London to study TRV027 in the context of COVID-19. The company employs a specialized approach using G protein biased ligands to enhance the efficacy and safety of its therapeutics, addressing the limitations of existing GPCR-targeted drugs.

Pulmonx Corporation is a medical technology company specializing in minimally invasive solutions for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), particularly severe emphysema. Its primary offerings include the Zephyr Endobronchial Valve, designed for patients with hyperinflation due to emphysema, as well as the Chartis Pulmonary Assessment System, which assesses collateral ventilation, and the StratX Lung Analysis Platform, a cloud-based service that analyzes computed tomography data to identify suitable treatment areas. Pulmonx aims to improve the quality of life for patients who remain symptomatic despite medical management and may not be candidates for surgical interventions. The company has received FDA pre-market approval for the Zephyr Valve and has established a global presence, serving markets in the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. Founded in 1995 and headquartered in Redwood City, California, Pulmonx has become a leader in interventional procedures for COPD, supported by extensive clinical evidence demonstrating the effectiveness of its technologies.

HTG Molecular Diagnostics is a commercial-stage life sciences company based in Tucson, Arizona, that specializes in precision medicine through its innovative molecular profiling technology. The company provides a range of products, including instruments, assay kits, and software, which are integrated into the HTG EdgeSeq platform. This platform automates sample processing and allows for the rapid, reliable profiling of numerous molecular targets from minimal biological samples. HTG's offerings include various molecular profiling panels designed for oncology and immuno-oncology applications, among others. The company serves a diverse clientele, including biopharmaceutical companies, academic research institutions, and molecular testing laboratories, distributing its products directly in the United States and Europe, as well as through international distributors. HTG Molecular Diagnostics has established partnerships with industry leaders to enhance its research and development efforts, further solidifying its role in advancing diagnostic applications and translational medicine. The company was founded in 1997 and was previously known as HTG, Inc. before rebranding in 2011.

diaDexus is a privately held biotechnology company based in the United States, specializing in the discovery, development, and commercialization of diagnostic products. The company is known for its lead product, the PLAC Test, which measures Lp-PLA2, an enzyme linked to vascular inflammation and critical in assessing the risk of coronary heart disease and ischemic stroke associated with atherosclerosis. This test is notable for being the only FDA-cleared blood test designed to aid in risk assessment for these cardiovascular conditions. In addition to the PLAC Test, diaDexus develops a range of diagnostic test kits for various health conditions, including liver disease, cancer markers, renal disease, diabetes, and electrolyte imbalances. The company primarily operates in the United States, with additional presence in Europe and other regions, contributing to its overall revenue.